Navigation Links
Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2011 Financial Results and Announces Presentations at the American Association for the Study of Liver Diseases Meeting (AASLD)
Date:10/26/2011

CAMBRIDGE, Mass., Oct. 26, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) announced today that it will report its financial results for the third quarter of 2011 on Wednesday, November 2, 2011 after U.S. financial markets close.

Idenix management will host a conference call at 4:30 p.m. ET on Wednesday, November 2, 2011 to discuss the company's financial results for the third quarter of 2011 and provide an update on the company's development programs.

To access the call please dial (877) 640-9809 U.S./Canada or (914) 495-8528 International and enter passcode 22292830. There will also be a slide presentation available to accompany the conference call, which can be accessed on our website in the Idenix Investor Center at www.idenix.com.  To listen to a live webcast of the call, go to "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 10 minutes before the call to ensure a timely connection. A replay of the conference call and webcast will be available until November 16, 2011. To access the replay, please dial (855) 859-2056 U.S./Canada or (404) 537-3406 International and enter the passcode 22292830.

American Association for the Study of Liver Diseases Meeting (AASLD)
Idenix will present two posters at AASLD in San Francisco, California:

  • McCarville, et al, "Patterns of NS5B mutations in a 3-day clinical trial of HCV non-nucleoside polymerase inhibitor IDX375" will be presented in a poster session on November 5, 2011 starting at 2:00pm PT
  • McCarville, et al, "In vivo resistance profile of IDX320 after 3 days of dosing in genotype 1 HCV-infected patients" will be presented in a poster session on November 5, 2011 starting at 2:00pm PT

About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033  (media)
Eric Hoffman (617) 224-4485 (investors)


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
2. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
3. Idenix Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Idenix Pharmaceuticals Reports First Quarter 2011 Financial Results
5. Idenix Pharmaceuticals Prices Public Offering of Common Stock
6. Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
7. Idenix Announces Data Presentations at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
10. Idenix to Host Conference Call Discussing Fourth Quarter and Year End 2010 Financial Results
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
Breaking Medicine News(10 mins):